DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma - PubMed (original) (raw)
Review
DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma
D C Allison et al. J Surg Oncol. 1998 Mar.
Abstract
Background and objectives: The 5-year survival rates after resection of pancreatic carcinoma have recently increased and are predicted by tumor size, DNA content, and lymph node metastases at the time of resection. However, whether the 10-year survival rates have also increased and are similarly predicted by these factors is not known.
Methods: The influence of preoperative imaging tests, alcohol consumption, cigarette smoking, K-ras mutations, anatomic location, details of surgical resection, pathologic findings, and tumor DNA content on survival was tested for 96 patients after a successful resection of a pancreatic carcinoma with 17 patients being followed for more than 5 years.
Results: The 5- and 10-year patient survival rates were 18% and 3%, respectively. Univariate and multivariable analyses showed that tumor DNA content, pathologic tumor size, and lymph node metastases were the strongest prognostic indicators for long-term patient survival, although the importance of tumor size may diminish 2 or more years after resection. Surprisingly, the 11 patients with diploid carcinomas > or = 4 cm had an estimated 10-year survival rate of 36%.
Conclusion: These results show that the 10-year survival rate for pancreatic carcinoma remains very low, although the subset of patients with biologically favorable tumors has a prolonged survival and possible cure after resection.
Similar articles
- Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma.
Kimura K, Amano R, Nakata B, Yamazoe S, Hirata K, Murata A, Miura K, Nishio K, Hirakawa T, Ohira M, Hirakawa K. Kimura K, et al. World J Surg Oncol. 2014 Nov 27;12:360. doi: 10.1186/1477-7819-12-360. World J Surg Oncol. 2014. PMID: 25429841 Free PMC article. - Significance of lymph node metastases in the surgical management of pancreatic head carcinoma.
Benassai G, Mastrorilli M, Mosella F, Mosella G. Benassai G, et al. J Exp Clin Cancer Res. 1999 Mar;18(1):23-8. J Exp Clin Cancer Res. 1999. PMID: 10374672 - Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy.
Fortner JG, Klimstra DS, Senie RT, Maclean BJ. Fortner JG, et al. Ann Surg. 1996 Feb;223(2):147-53. doi: 10.1097/00000658-199602000-00006. Ann Surg. 1996. PMID: 8597508 Free PMC article. - [Pancreatectomy for adenocarcinoma: prognostic factors, recommendations for pathological reports].
Chatelain D, Fléjou JF. Chatelain D, et al. Ann Pathol. 2002 Oct;22(5):422-31. Ann Pathol. 2002. PMID: 12483163 Review. French. - Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base.
Johnston WC, Hoen HM, Cassera MA, Newell PH, Hammill CW, Hansen PD, Wolf RF. Johnston WC, et al. HPB (Oxford). 2016 Jan;18(1):21-8. doi: 10.1016/j.hpb.2015.07.009. Epub 2015 Dec 21. HPB (Oxford). 2016. PMID: 26776847 Free PMC article. Review.
Cited by
- Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial.
Combs SE, Habermehl D, Kieser M, Dreher C, Werner J, Haselmann R, Jäkel O, Jäger D, Büchler MW, Debus J. Combs SE, et al. BMC Cancer. 2013 Sep 14;13:419. doi: 10.1186/1471-2407-13-419. BMC Cancer. 2013. PMID: 24034562 Free PMC article. Clinical Trial. - Pancreatic Cancer: 80 Years of Surgery-Percentage and Repetitions.
Gudjonsson B. Gudjonsson B. HPB Surg. 2016;2016:6839687. doi: 10.1155/2016/6839687. Epub 2016 Oct 25. HPB Surg. 2016. PMID: 27847403 Free PMC article. Review. - Limited value of positron emission tomography in treatment of pancreatic cancer: surgeon's view.
Kasperk RK, Riesener KP, Wilms K, Schumpelick V. Kasperk RK, et al. World J Surg. 2001 Sep;25(9):1134-9. doi: 10.1007/BF03215860. World J Surg. 2001. PMID: 11571948 Clinical Trial. - RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma.
Whittle MC, Izeradjene K, Rani PG, Feng L, Carlson MA, DelGiorno KE, Wood LD, Goggins M, Hruban RH, Chang AE, Calses P, Thorsen SM, Hingorani SR. Whittle MC, et al. Cell. 2015 Jun 4;161(6):1345-60. doi: 10.1016/j.cell.2015.04.048. Epub 2015 May 21. Cell. 2015. PMID: 26004068 Free PMC article. - K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.
Li T, Zheng Y, Sun H, Zhuang R, Liu J, Liu T, Cai W. Li T, et al. Med Oncol. 2016 Jul;33(7):61. doi: 10.1007/s12032-016-0777-1. Epub 2016 May 25. Med Oncol. 2016. PMID: 27225938 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous